Heineken Warns UK Pubs: Weight-Loss Drugs Threaten Beer Sales

Heineken has told British pubs and bars that the boom in weight-loss drugs could cut beer and cider sales — and it wants landlords serving half pints and food plates before that happens.

The world's second largest brewer sent a presentation to British hospitality customers earlier this month, warning that GLP-1 medication — led by Ozempic and Wegovy — can reduce the desire to drink alcohol. The result, according to the document revealed by Reuters, could be "fullness and fewer serves" of pints across UK pubs and bars.

The stakes are real. British pubs, bars and restaurants sold almost £14bn worth of beer in the year to February, Heineken said. Less than £300m of that — barely 2% — came from no- and low-alcohol products.

What does the presentation actually say?

Heineken's document doesn't mince words about the trend. It warned that the GLP-1 era could make the multi-pint drinking session a less frequent occurrence in British pubs.

The company's advice to operators is practical:

• Promote half pints instead of full pints
• Push low- and zero-alcohol options harder
• Pair drinks with small plates of food

The alternative, the presentation implies, is declining customer visits and lower spending per visit.

The numbers behind the warning

GLP-1 use has surged as consumers chase rapid weight loss. Some 10 million people in the US turned to weight-loss medication last year, according to research by JP Morgan. That's roughly one in 33 Americans — a customer base brewers can no longer treat as a fringe group.

Heineken said the presentation was shared as part of its regular engagement with UK businesses to help them understand how consumer habits are evolving. "We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," the company told Reuters.

The trends Heineken has already identified among GLP-1 users include smaller serves, lower-alcohol drinks and more premium products. The brewer noted these also align with broader market shifts as younger generations change their drinking habits.

Alongside its eponymous lager, Heineken owns Amstel, the Mexican lager Sol and Strongbow cider — a portfolio that gives it direct exposure to the British pub trade.

Rivals aren't all singing from the same sheet

Not every major brewer reads the data the same way. Diageo, the Guinness maker, has told investors that any impact from GLP-1 drugs going mainstream should be manageable. Carlsberg went further, telling Reuters that current data does not support the view that weight-loss drugs are affecting beer consumption trends.

But independent research points the other way. Surveys by Circana, NIQ and KAM all found reduced drinking among GLP-1 users.

What does this change for pub operators?

For publicans, the message is about menu engineering rather than panic. If GLP-1 users drink less but trade up to premium products, the margin per serve can partly offset the lost volume. Small plates capture food spend that used to go to a second or third pint.

The £300m no- and low-alcohol slice of a £14bn market also leaves a lot of headroom. Heineken clearly sees growth there — and it's telling its UK customers to build that shelf space now, before the multi-pint session becomes a rarity rather than the ritual.